stockrowAurinia Pharmaceuticals Inc (AUPH) vs Celldex Therapeutics, Inc. (CLDX)
- Aurinia Pharmaceuticals Inc AUPH 16.41 +1.23%
- Celldex Therapeutics, Inc. CLDX 29.95 +5.94%
Aurinia Pharmaceuticals Inc and Celldex Therapeutics, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Celldex Therapeutics, Inc. are of similar size ($2.2B and $2.2B). Celldex Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.8×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 21.0% against −88.3%. Aurinia Pharmaceuticals Inc has the higher net margin (97.7% vs −33,883.8%) and the higher return on invested capital (43.0% vs 0.00%). Across the 18 metrics below, Aurinia Pharmaceuticals Inc leads on 14 and Celldex Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | AUPH | CLDX | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.62% | 100.00% | 65.16% |
| Operating margin | 44.78% | (36,733.82%) | 0.00% |
| Net margin | 97.68% | (33,883.77%) | 0.00% |
| Free cash flow margin | 55.02% | (27,294.81%) | 0.00% |
| Return on equity | 61.42% | (43.88%) | (50.12%) |
| Return on assets | 46.45% | (40.76%) | (45.60%) |
| Return on invested capital | 42.95% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack